MHT was associated with increased medium-to-large HDL particle count and decreased small-to-medium LDL particle and glycine concentration, indicating a potentially improved lipid profile.
92.74% of participants rated the clinical performance of Halova ovules as excellent when used alone, and 95.71% when used with other medications. Symptoms of vaginal dryness and dyspareunia were significantly reduced.
Statistically significant improvements were reported in hot flashes and co-occurring symptoms in 5 of 6 acupuncture studies, one acupressure study, one moxibustion study, and one of two studies on Chinese herbal medicine.
Participants expressed interest in IMGV, highlighting the need for education about menopause and integrative health interventions, and the potential for improved access to care.
MHT has been shown to decrease the risk of all fractures, with significant reductions in vertebral and hip fractures among users compared to non-users. Studies indicate a 33% decreased risk of vertebral fractures and a 27% decreased risk of non-vertebral fractures in women using MHT.
Expected positive outcomes include improved ovarian function as indicated by increased AMH levels and decreased FSH levels, along with better menstrual regularity and overall reproductive health.
Significant improvement in handgrip strength and increased myosin regulatory light chain phosphorylation; no change in bone turnover markers.
Significant improvements in vaginal pH and pathogenic flora were observed, with 60% of premenopausal women and 81.3% of postmenopausal women experiencing improvement in genitourinary symptoms after treatment.
CGRP receptor antagonists showed a statistically significant drug effect on pain freedom and reduction of bothersome symptoms in female patients, with effects ranging from 7.4% to 12.4% compared to a lower effect in male patients.
Both TRE and CR groups experienced significant weight loss compared to the control group by month 12, indicating the effectiveness of these dietary interventions for obesity management.
Some studies suggest that oestrogen replacement therapy may improve muscle size and strength in postmenopausal females, although evidence is inconsistent.
Potential positive outcomes include reduced headache frequency and severity, improved quality of life for women suffering from hormonal-related headaches, and enhanced understanding of gender-specific treatment efficacy.
Increased working memory-related brain activation was observed, suggesting potential functional compensation for structural changes due to treatment. Women with breast cancer exhibited higher estimated brain age and lower regional gray matter volume compared to controls.
Total bladder bacterial burden was associated with a 3.1 times increased risk of rUTI relapse within six months after EF, indicating that higher bacterial loads may lead to poorer treatment outcomes.
Postmenopausal women with metabolically healthy overweight/obesity and metabolically unhealthy normal weight had a higher risk of cardiovascular disease compared to those with metabolically healthy normal weight.
Postmenopausal women with RA experienced a significant risk of accelerated loss of muscle mass over time, with TNFα inhibitors showing a protective effect against this loss.
The study found that women with a history of severe VMS had a higher prevalence of CCTA-detected coronary atherosclerosis compared to those with mild or no VMS. This association was significant for severe VMS lasting more than 5 years or starting before menopause.